The injection of TIM-3(+) AML cells into immunodeficient mice led to AML reconstitution, and these data—plus the observation that TIM-3 is not expressed in normal tissues and HSCs—make it an attractive target. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.